Effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum in PARAGON‐HF

Xiaowen Wang,Orly Vardeny,Brian Claggett,Muthiah Vaduganathan,Sheila M. Hegde,Hicham Skali,Maria A. Pabon,Alberto Foà,Safia Chatur,Annamaria Kosztin,Eileen O'Meara,Jean Rouleau,Margaret Redfield,Carolyn S.P. Lam,Michael Zile,Milton Packer,Amil M. Shah,Maja Cikes,Mauro Gori,Bela Merkely,Marc A. Pfeffer,John J.V. McMurray,Scott D. Solomon

DOI: https://doi.org/10.1002/ejhf.3535

2024-12-17

European Journal of Heart Failure

Abstract:A summary of effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum. All participants in PARAGON‐HF were divided into three age groups: <65 years, 65–74 years, and ≥75 years. Compared to younger participants, older participants had worse clinical outcomes (A), derived similar benefits from sacubitril/valsartan (B), despite being more likely to develop hypotension when randomized to sacubitril/valsartan (C). CV, cardiovascular; aHR, adjusted hazard ratio; GLS, global longitudinal strain; HFH, heart failure hospitalization; LA, left atrial; LV, left ventricular; LVEF, left ventricular ejection fraction; PASP, pulmonary artery systolic pressure; RV, right ventricular. Aims To evaluate clinical outcomes, echocardiographic features, and the efficacy and safety of sacubitril/valsartan compared to valsartan across age groups in the PARAGON‐HF trial. Methods and results A total of 4796 participants ≥50 years of age with chronic heart failure (HF) and left ventricular ejection fraction (LVEF) ≥45% were divided into three age groups: <65 years (n = 825), 65–74 years (n = 1772), and ≥75 years (n = 2199). Echocardiograms of 1097 patients were analysed in a standardized fashion at a core imaging laboratory. The primary composite outcome was total HF hospitalizations and cardiovascular (CV) death. Older patients were more likely to experience primary composite outcomes (compared to patients <65 years, adjusted rate ratio [aRR] for ≥75 years: 1.39, 95% confidence interval [CI] 1.21–1.61), total HF hospitalization (aRR 1.27, 95% CI 1.09–1.49), and CV death (adjusted hazard ratio [aHR] 2.04, 95% CI 1.44–2.87). Age did not modify the effect of sacubitril/valsartan compared to valsartan on primary composite endpoint (pinteraction = 0.79) in the overall population or in those with LVEF ≤57%. Older adults randomized to sacubitril/valsartan were more likely to develop hypotension compared to those receiving valsartan (pinteraction = 0.026). Older patients had smaller left ventricular chamber sizes, higher LVEF, and were more likely to have abnormal measures of diastolic function. Conclusion Older patients with HF with preserved ejection fraction had higher event rates than younger patients, more adverse events overall, and more hypotension when treated with sacubitril/valsartan; however, the treatment benefits of sacubitril/valsartan were retained in older patients.

cardiac & cardiovascular systems